Development of PCSK9 Inhibitors: A Paradigm Shift in the Treatment of Hypercholesterolemia

Date & Time

Mar 6th at 10:30 AM until 12:30 PM



Rating ( votes)

Dubbed as “new statins”, development of PCSK9 inhibitors has gained wide interest among clinicians and clinical pharmacologists and is often seen as a paradigm shift in the treatment of hyperlipidemia. Thus, this session is intended to showcase the unmet medical need and the translational development including PK/PD modeling and dose selection of PCSK9 inhibitors to inform and accelerate pivotal trials. The session will also focus on development of clinical pharmacology profile and utilizing decision tools such as Model based Meta-Analysis to enhance the understanding of PK-PD relationships using this novel biologics as an example. A special topic on pediatric hyperlipidemia and development of PCSK9 inhibitors for pediatric patients will also be discussed.